JUUL continues to block and prevent FDA regulations, investing more than $1 million in lobbying efforts in the second quarter of 2019 alone. It has also invested millions – more than $4 million so far – to try to beat a San Francisco ballot initiative to stop sales of e-cigarettes in the city.
Meanwhile, JUUL has failed to subject its products to the level of independent, clinical investigation needed to substantiate any claims of effective cessation, nor has the company applied to the FDA to be approved as a product to help smokers quit.